
Akin Osibogun

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2772477/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Effect of social marketing on the knowledge, attitude, and uptake of pap smear among women residing in an urban slum in Lagos, Nigeria. BMC Women's Health, 2022, 22, 42.	0.8	3
2	Presenting Symptoms and Predictors of Poor Outcomes Among 2,184 Patients with COVID-19 in Lagos State, Nigeria. International Journal of Infectious Diseases, 2021, 102, 226-232.	1.5	44
3	Volunteering during the COVID-19 pandemic: Attitudes and perceptions of clinical medical and dental students in Lagos, Nigeria. Nigerian postgraduate medical journal, The, 2021, 28, 1.	0.1	13
4	Outcomes of COVID-19 patients with comorbidities in southwest Nigeria. PLoS ONE, 2021, 16, e0248281.	1.1	53
5	â€~Long COVID': persistent COVID-19 symptoms in survivors managed in Lagos State, Nigeria. BMC Infectious Diseases, 2021, 21, 304.	1.3	65
6	Clinical and Demographic Characteristics of COVID-19 patients in Lagos, Nigeria: A Descriptive Study. Journal of the National Medical Association, 2021, 113, 301-306.	0.6	19
7	Morbidity and mortality outcomes of COVID-19 patients with and without hypertension in Lagos, Nigeria: a retrospective cohort study. Global Health Research and Policy, 2021, 6, 26.	1.4	21
8	From Ebola to COVID-19: emergency preparedness and response plans and actions in Lagos, Nigeria. Globalization and Health, 2021, 17, 79.	2.4	15
9	Psychosocial health effects of Covid-19 infection on persons in treatment centers in Lagos, Nigeria. Brain, Behavior, & Immunity - Health, 2021, 16, 100284.	1.3	8
10	Association between anxiety, alcohol, poly-tobacco use and waterpipe smoking: A cross-sectional study in Lagos, Nigeria. Nigerian postgraduate medical journal, The, 2021, 28, 117.	0.1	4
11	Electronic cigarette use among adolescents and young adults in Nigeria: Prevalence, associated factors and patterns of use. PLoS ONE, 2021, 16, e0258850.	1.1	9
12	Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials. BMC Infectious Diseases, 2021, 21, 1170.	1.3	46
13	The impact of HIV-1 subtypes on virologic and immunologic treatment outcomes at the Lagos University Teaching Hospital: A longitudinal evaluation. PLoS ONE, 2020, 15, e0238027.	1.1	2
14	Clinical presentation, case management and outcomes for the first 32 COVID-19 patients in Nigeria. Pan African Medical Journal, 2020, 35, 24.	0.3	46
15	Epidemiological trends of coronavirus disease 2019 in Nigeria: From 1 to 10,000. Nigerian postgraduate medical journal, The, 2020, 27, 271.	0.1	3
16	Predictive ability of symptomatology in COVID-19 during Active case search in Lagos State, Nigeria. Nigerian postgraduate medical journal, The, 2020, 27, 280.	0.1	2
17	Clinical characteristics, predictors of symptomatic coronavirus disease 2019 and duration of hospitalisation in a cohort of 632 Patients in Lagos State, Nigeria. Nigerian postgraduate medical journal, The, 2020, 27, 285.	0.1	13
18	Knowledge and risk perception of e-cigarettes and hookah amongst youths in Lagos State, Nigeria: An exploratory study. Nigerian postgraduate medical journal, The, 2020, 27, 384.	0.1	10

Akin Osibogun

#	Article	IF	CITATIONS
19	Title is missing!. , 2020, 15, e0238027.		0
20	Title is missing!. , 2020, 15, e0238027.		0
21	Title is missing!. , 2020, 15, e0238027.		0
22	Title is missing!. , 2020, 15, e0238027.		0
23	Title is missing!. , 2020, 15, e0238027.		0
24	Title is missing!. , 2020, 15, e0238027.		0
25	Patients' and healthcare providers' perceptions and practices regarding hypertension, pharmacy-based care, and mHealth in Lagos, Nigeria. Journal of Hypertension, 2019, 37, 389-397.	0.3	18
26	Medication adherence and patient satisfaction among hypertensive patients attending outpatient clinic in Lagos University Teaching Hospital, Nigeria. Nigerian postgraduate medical journal, The, 2019, 26, 129.	0.1	14
27	Low uptake of hypertension care after community hypertension screening events in Lagos, Nigeria. Global Health Action, 2018, 11, 1548006.	0.7	4
28	Pharmacy-based hypertension care employing mHealth in Lagos, Nigeria – a mixed methods feasibility study. BMC Health Services Research, 2018, 18, 934.	0.9	33
29	Clinically relevant thresholds for ultrasensitive HIV drug resistance testing: a multi-country nested case-control study. Lancet HIV,the, 2018, 5, e638-e646.	2.1	56
30	High levels of preâ€treatment HIV drug resistance and treatment failure in Nigerian children. Journal of the International AIDS Society, 2016, 19, 21140.	1.2	32
31	Enablers and barriers for implementing high-quality hypertension care in a rural primary care setting in Nigeria: perspectives of primary care staff and health insurance managers. Global Health Action, 2016, 9, 29041.	0.7	24
32	How Group-Based Cardiovascular Health Education Affects Treatment Adherence and Blood Pressure Control among Insured Hypertensive Nigerians: A Pre-Test, Post-Test Study. World Journal of Cardiovascular Diseases, 2015, 05, 181-198.	0.0	8
33	Perceptions of inhibitors and facilitators for adhering to hypertension treatment among insured patients in rural Nigeria: a qualitative study. BMC Health Services Research, 2014, 14, 624.	0.9	31
34	Anti-Hypertensive Prescription and Cost Patterns in an Outpatient Department of a Teaching Hospital in Lagos State Nigeria. Open Journal of Preventive Medicine, 2014, 04, 156-163.	0.2	6
35	Patterns of HIV-1 Drug Resistance After First-Line Antiretroviral Therapy (ART) Failure in 6 Sub-Saharan African Countries: Implications for Second-Line ART Strategies. Clinical Infectious Diseases, 2012, 54, 1660-1669.	2.9	144
36	Cohort Profile: The PharmAccess African (PASER-M) and the TREAT Asia (TASER-M) Monitoring Studies to Evaluate Resistance—HIV drug resistance in sub-Saharan Africa and the Asia-Pacific. International Journal of Epidemiology, 2012, 41, 43-54.	0.9	53

Akin Osibogun

#	Article	IF	CITATIONS
37	Building Capacity for the Assessment of HIV Drug Resistance: Experiences From the PharmAccess African Studies to Evaluate Resistance Network. Clinical Infectious Diseases, 2012, 54, S261-S265.	2.9	10
38	Early Warning Indicators for Population-Based Monitoring of HIV Drug Resistance in 6 African Countries. Clinical Infectious Diseases, 2012, 54, S294-S299.	2.9	23
39	Second-Line Antiretroviral Treatment Successfully Resuppresses Drug-Resistant HIV-1 After First-Line Failure: Prospective Cohort in Sub-Saharan Africa. Journal of Infectious Diseases, 2012, 205, 1739-1744.	1.9	61
40	Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study. Lancet Infectious Diseases, The, 2012, 12, 307-317.	4.6	162
41	HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Lancet Infectious Diseases, The, 2011, 11, 750-759.	4.6	258
42	Unnecessary Antiretroviral Treatment Switches and Accumulation of HIV Resistance Mutations; Two Arguments for Viral Load Monitoring in Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 58, 23-31.	0.9	176
43	Development and evaluation of a patient centered cardiovascular health education program for insured patients in rural Nigeria (QUICK - II). BMC Public Health, 2011, 11, 171.	1.2	9
44	Health: A critical determinant of national development. Annals of Health Research, 0, , 1-10.	0.1	0